Jose Javier Sanchez
Overview
Explore the profile of Jose Javier Sanchez including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
53
Citations
5520
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Griswold A, Rajabli F, Gu T, Arvizu J, Golightly C, Whitehead P, et al.
medRxiv
. 2024 Apr;
PMID: 38645114
Introduction: Plasma phosphorylated threonine-181 of Tau and amyloid beta are biomarkers for differential diagnosis and preclinical detection of Alzheimer disease (AD). Given differences in AD risk across diverse populations, generalizability...
2.
Quinones Z, Li D, McIntosh S, Avendano E, Sanchez J, DiMare-Hering C, et al.
Nicotine Tob Res
. 2022 Jan;
24(6):909-913.
PMID: 35084495
Introduction: Secondhand smoke (SHS) exposure poses risks to pregnant women and children. Though smoking among pregnant women in many low- and middle-income countries is low, exposure to SHS might be...
3.
de Luna D, Sanchez J, Peguero M, Garcia W, Liciaga S, Brito F, et al.
Rev Panam Salud Publica
. 2020 Sep;
44:e36.
PMID: 32973895
Objective: To define the antimicrobial resistance profiles of the microorganisms most commonly isolated from hospitalized adult patients in Dominican Republic (DR). Methods: A retrospective, cross-sectional study of phenotypic antimicrobial susceptibility...
4.
Novelli S, Martin A, Sanchez J, Espeso M, Mozos A, Briones J
Eur J Dermatol
. 2020 Aug;
30(4):397-403.
PMID: 32815814
Background: Advanced-stage mycosis fungoides/Sézary syndrome (aMF/SS) has a dismal outcome. The only curative treatment is allogeneic stem cell transplantation (allo-SCT) but this is limited to selected candidates, thus palliative therapy...
5.
Ossip D, Diaz S, Quinones Z, McIntosh S, Dozier A, Chin N, et al.
J Smok Cessat
. 2017 Nov;
11(2):99-107.
PMID: 29104673
Engaging partners for tobacco control within low and middle income countries (LMICs) at early stages of tobacco control presents both challenges and opportunities in the global effort to avert the...
6.
Provencio M, Sabin P, Gomez-Codina J, Torrente M, Calvo V, Llanos M, et al.
PLoS One
. 2017 May;
12(5):e0177204.
PMID: 28493986
Background: Follicular lymphoma is the second most common non-Hodgkin lymphoma in the United States and Europe. However, most of the prospective randomized studies have very little follow-up compared to the...
7.
Wu N, Huang Y, Zou Z, Gimenez-Capitan A, Yu L, Hu W, et al.
Oncol Lett
. 2017 Apr;
13(3):1826-1834.
PMID: 28454330
Chemotherapy drugs, including 5-fluorouracil (5-FU), oxaliplatin and docetaxel, are commonly used in the treatment of gastric cancer (GC). Apoptosis-relevant genes may be associated with drug resistance. In the present study,...
8.
Ossip D, Quinones Z, Diaz S, Thevenet-Morrison K, Fisher S, Holderness H, et al.
J Smok Cessat
. 2016 Dec;
11(4):239-249.
PMID: 28025600
Introduction: Tobacco use and harm continue to increase in low- and middle income countries (LMICs) globally. Smoking cessation is the most effective means of reducing morbidity and mortality from tobacco...
9.
Prucha M, Fisher S, McIntosh S, Grable J, Holderness H, Thevenet-Morrison K, et al.
Int J Environ Res Public Health
. 2015 Apr;
12(4):4060-75.
PMID: 25872018
Tobacco use is increasing globally, particularly in low and middle-income countries like the Dominican Republic (DR) where data have been lacking. Health care worker (HCW) interventions improve quit rates; asking...
10.
Karachaliou N, Costa C, Gimenez-Capitan A, Molina-Vila M, Bertran-Alamillo J, Mayo C, et al.
J Thorac Oncol
. 2013 Feb;
8(3):295-300.
PMID: 23407556
Introduction: Lung adenocarcinoma patients harboring EGFR activating mutations attain improved progression-free survival (PFS) with treatment with epidermal growth factor receptor tyrosine kinase inhibitors. However, patients ultimately relapse, indicating that other...